Abbisko Therapeutics Co, Ltd
Clinical trials sponsored by Abbisko Therapeutics Co, Ltd, explained in plain language.
-
New combo therapy aims to shrink liver tumors in hard-to-treat patients
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug (ABSK-011) combined with atezolizumab or standard care in about 118 people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. Participants must have a specific genetic mark…
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New drug tested for advanced cancers: early safety check
Disease control OngoingThis early-phase study tests a new oral drug called ABSK121-NX in about 169 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for any signs that th…
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 26, 2026 07:50 UTC
-
Hope for rare joint tumor: new drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug called Pimicotinib (ABSK021) for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that grows in joints and tendons. About 94 adults with tumors that cannot be removed by surgery will receive either the drug or a placebo for…
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 26, 2026 07:27 UTC